IDEAYA Biosciences (IDYA) Stock Price
IDEAYA Biosciences Price
Over the last 5 years IDEAYA Biosciences grew revenue by 62.1% annually, reaching 218.71 M USD. For IDEAYA Biosciences, the net margin of -52.0% is up versus -170.1% a few years ago. The consensus 12-month price target for IDEAYA Biosciences is 60.00 USD, about 90.1% above where the stock trades today. Of 22 analysts, 20 rate the stock a buy — an overall Buy consensus.
IDEAYA Biosciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
IDEAYA Biosciences business model & stock analysis
Frequently asked questions about IDEAYA Biosciences
IDEAYA Biosciences Inc is a precision medicine-focused biotechnology company. Their business model revolves around leveraging their expertise in synthetic lethality and cancer biology to discover and develop targeted oncology therapeutics. By combining their innovative drug discovery platforms and partnerships, IDEAYA aims to address specific genetic alterations in cancer cells. This approach allows them to develop personalized medicines for patients based on the underlying drivers of their disease. IDEAYA's business model is centered on advancing their pipeline of novel therapies and collaborating with strategic partners to bring innovative treatments to patients in need.
IDEAYA Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of IDEAYA Biosciences Inc in the market include leading biopharmaceutical companies such as Bristol-Myers Squibb, Novartis AG, Pfizer Inc, and Roche Holding AG. These companies also operate in the biotechnology sector and offer innovative solutions for various diseases and medical conditions. IDEAYA Biosciences Inc competes with these industry giants through its cutting-edge research and development, strategic partnerships, and focus on targeted therapies for oncology and immuno-oncology. By offering unique approaches to precision medicine, IDEAYA Biosciences Inc aims to carve a niche for itself in the competitive biopharmaceutical market.
IDEAYA Biosciences Inc is a clinical-stage oncology-focused precision medicine company. Founded in 2015, IDEAYA is dedicated to leveraging its Synthetic Lethality platform to develop personalized therapies for patients with genetically defined cancers. The company's innovative approach involves using biomarkers to identify patients who are most likely to respond to their targeted cancer therapies. IDEAYA's collaborative partnerships, such as the one with Pfizer, enable it to accelerate the development of its portfolio of drug candidates. With a strong track record and a commitment to improving patient outcomes, IDEAYA Biosciences Inc is well-positioned to make a positive impact in the field of precision oncology.
IDEAYA Biosciences Inc has achieved several significant milestones. The company successfully completed its initial public offering in May 2019. IDEAYA Biosciences Inc also entered into a strategic collaboration with GlaxoSmithKline (GSK) in October 2019 to develop targeted therapies for solid tumors. They have advanced their oncology pipeline, with notable progress in their Synthetic Lethality programs, including the initiation of Phase 1/2 clinical trials. In addition, IDEAYA Biosciences Inc expanded its oncology collaboration with Novartis in December 2019. They have made substantial strides in their research and development efforts, bringing innovative and precision medicine approaches to cancer treatment.
IDEAYA Biosciences Inc is primarily present in the United States.
IDEAYA Biosciences Inc represents a commitment to scientific innovation and improving patient outcomes. The company focuses on developing targeted oncology therapies by leveraging its expertise in synthetic lethality and immuno-oncology. IDEAYA embraces a corporate philosophy centered around collaboration, integrity, and patient-centricity. By actively partnering with leading biopharmaceutical companies and institutions, IDEAYA aims to accelerate the development of transformative medicines. The company's dedication to precision medicine and cutting-edge technologies drives its mission to address unmet needs in oncology and provide hope for patients worldwide. IDEAYA Biosciences Inc is dedicated to delivering value to patients, healthcare providers, and stakeholders through its innovative research and therapeutic advancements.
Analysts currently set an average price target of 57.00 USD for the IDEAYA Biosciences stock (median: 60.00 USD), implying +78.0 % versus the latest price. The consensus is based on 22 analyst ratings.
22 analysts currently rate the IDEAYA Biosciences stock: 20 recommend buying, 2 holding and 0 selling. For 2026, analysts expect IDEAYA Biosciences to generate revenue of 40.07 M USD and earnings per share of -4.57 USD.
Converted at the current exchange rate, the IDEAYA Biosciences share trades at 28.22 EUR (31.57 USD).
The IDEAYA Biosciences share (IDYA) is listed on 3 stock exchanges, including: NASDAQ (IDYA), Frankfurt (30J.F), München (30J.MU).
IDEAYA Biosciences Inc is a leading biopharmaceutical company focused on the treatment of cancer. The company offers a wide range of products and services aimed at treating cancer at the cellular level. The company has an innovative business model based on the combination of three core elements: research and development, clinical trials, and partnerships. Research and Development IDEAYA Biosciences Inc focuses on developing drugs that have the potential to combat cancer at the cellular level. The company uses a range of technologies and methods to identify and validate potential drug candidates, including its proprietary platforms for drug discovery and development. These platforms enable the company to quickly and efficiently identify and develop promising new therapies. Clinical Trials IDEAYA Biosciences Inc conducts clinical trials to demonstrate the efficacy and safety of new drugs. The company is currently conducting clinical trials at multiple locations worldwide to advance its pipeline of innovative cancer therapies. The clinical trials focus on various types of cancer, such as prostate cancer, breast cancer, advanced melanoma, and others. Partnerships IDEAYA Biosciences Inc collaborates with various leading companies and universities to advance its research. The partnerships include strategic alliances, acquisitions, and collaboration in drug development and manufacturing. Through these partnerships, IDEAYA Biosciences Inc can leverage its resources and bring its products to market faster. Products IDEAYA Biosciences Inc has launched a wide range of products and services focused on cancer treatment. One product highlight, for example, is the proprietary/oncology inhibitor IDEA-316. This drug has shown promising results in preclinical development and has the potential to provide innovative solutions for cancer patients suffering from inhibitor resistance. Overall, IDEAYA Biosciences Inc has an innovative business model aimed at combating cancer at the cellular level. The combination of research and development, clinical trials, and partnerships enables the company to quickly and efficiently identify and develop promising new therapies to help cancer patients.
The expected revenue of IDEAYA Biosciences is 40.07 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of IDEAYA Biosciences is -404.93 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IDEAYA Biosciences is currently -6.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IDEAYA Biosciences stock.
The price-to-sales ratio (P/S) of IDEAYA Biosciences is currently 69.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IDEAYA Biosciences stock.
The Eulerpool Quality Score for IDEAYA Biosciences is 5/10.
The ISIN of IDEAYA Biosciences is US45166A1025. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IDEAYA Biosciences is A2PJPB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IDEAYA Biosciences is IDYA. The ticker symbol is used to trade IDEAYA Biosciences shares on the stock exchange.
IDEAYA Biosciences stock
IDEAYA Biosciences Peer Group
IDEAYA Biosciences Ticker
IDEAYA Biosciences FIGI
All fundamentals and in-depth analysis of IDEAYA Biosciences
Our stock analysis for IDEAYA Biosciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IDEAYA Biosciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.